Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic disease that is associated with inflammatory bowel disease (IBD) in approximately 70% of cases. Although the pathogenesis is still unknown for both diseases, there is increasing evidence to indicate that they share a common underlying predisposition. Herein, we review the epidemiology, diagnosis, disease pathogenesis, and specific clinical features of the PSC-IBD phenotype. Patients with PSC-IBD have a distinct IBD phenotype with an increased incidence of pancolitis, backwash ileitis, and rectal sparing. Despite often having extensive colonic involvement, these patients present with mild intestinal symptoms or are even asymptomatic, which can delay the diagnosis of IBD. Although the IBD phenotype has been well characterized in PSC patients, the natural history and disease behavior of PSC in PSC-IBD patients is less well defined. There is conflicting evidence regarding the course of IBD in PSC-IBD patients who receive liver transplantation and their risk of recurrent PSC. IBD may also be associated with an increased risk of cholangiocarcinoma in PSC patients. Overall, the PSC-IBD population has an increased risk of developing colorectal neoplasia compared to the conventional IBD population. Lifelong annual surveillance colonoscopy is currently recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 13×
“Large-scale genome-wide association studies (GWAS) have identified close to 200 independent loci associated with IBD.(16,17) Most of these loci are shared between UC and CD.”
BackgroundInfluentialSellon, R. K., Tonkonogy, S., Schultz, M., Dieleman, L. A., Grenther, W., Balish, E., Rennick, D. M., & Sartor, R. B. (1998) · Infection and Immunity · doi:10.1128/iai.66.11.5224-5231.1998 · Cited by 1,483
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
Duboc, H., Rajca, S., Rainteau, D., Benarous, D., Maubert, M.-A., Quervain, E., Thomas, G., Barbu, V., Humbert, L., Despras, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302578 · Cited by 930
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717 · cited 1×
“Interestingly, in one large cohort describing the risk of cancer in PSC patients, CRN risk was only increased when IBD was also present.(85) Some have suggested that the increased risk of CRN in PSC-IBD patients could be related to the presence of longstanding underdiagnosed disease and colonic inflammation.”
BackgroundTlaskalová-Hogenová, H., Štěpánková, R., Kozáková, H., Hudcovic, T., Vannucci, L., Tučková, L., Rossmann, P., Hrnčíř, T., Kverka, M., Zákostelská, Z., et al. (2011) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.67 · Cited by 693
The bile acid receptor FXR is a modulator of intestinal innate immunity
Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803978 · Cited by 655
The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2616 · Cited by 391
Carcinogenicity of deoxycholate, a secondary bile acid
Bernstein, C., Holubec, H., Bhattacharyya, A. K., Nguyen, H., Payne, C. M., Zaitlin, B., & Bernstein, H. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0648-7 · Cited by 351
Alabraba, E., Nightingale, P., Gunson, B., Hubscher, S., Olliff, S., Mirza, D., & Neuberger, J. (2009) · Liver Transplantation · doi:10.1002/lt.21679 · Cited by 298 · cited 1×
“In a cohort of 230 PSC patients who underwent OLT, colectomy pre- and peri-OLT conferred a protective effect against rPSC in the transplanted graft.(59) Moreover, an intact colon prior to OLT was the strongest predictor of rPSC.”
BackgroundDistinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis
Vries, A. B. D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1956 · Cited by 253 · cited 22×
“Colonic involvement is the most often reported (37% to 82%), followed by ileocolic involvement (22% to 58%), and rarely isolated ileal involvement (2% to 5%).(6) In PSC-CD patients there is a lower frequency of stricturing and penetrating disease compared to patients with isolated CD.”
BackgroundResultInfluentialTabibian, J. H., O'Hara, S. P., Trussoni, C. E., Tietz, P. S., Splinter, P. L., Mounajjed, T., Hagey, L. R., & LaRusso, N. F. (2016) · Hepatology · doi:10.1002/hep.27927 · Cited by 223 · cited 4×
“Tabibian et al.30 used MDR2 knockout mice (a widely utilized animal model of PSC) to assess the role of the commensal microbiota in the pathogenesis of biliary injury.”
BackgroundMethodInfluentialGut microbiota and probiotics in chronic liver diseases
Cesaro, C., Tiso, A., Del Prete, A., Cariello, R., Tuccillo, C., Cotticelli, G., del Vecchio Blanco, C., & Loguercio, C. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.015 · Cited by 182
The gut-adherent microbiota of PSC–IBD is distinct to that of IBD
Quraishi, M. N., Sergeant, M., Kay, G., Iqbal, T., Chan, J., Constantinidou, C., Trivedi, P., Ferguson, J., Adams, D. H., Pallen, M., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311915 · Cited by 179
Zheng, H.-H., & Jiang, X.-L. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000576 · Cited by 159
Primary sclerosing cholangitis: diagnosis, prognosis, and management
Singh, S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.016 · Cited by 119 · cited 1×
“Furthermore, de-novo IBD after OLT has also been reported and it may develop in 14% to 30% of PSC patients up to 10 years after transplantation.(40) Retrospective studies comparing IBD activity before and after liver transplantation found that endoscopic colonic inflammation was more frequent after OLT, as was the rat…”
BackgroundJoshi, D., Bjarnason, I., Belgaumkar, A., O'Grady, J., Suddle, A., Heneghan, M. A., Aluvihare, V., Rela, M., Heaton, N., & Agarwal, K. (2013) · Liver International · doi:10.1111/j.1478-3231.2011.02677.x · Cited by 99 · cited 2×
“Joshi et al.(60) reviewed 110 PSC patients who underwent OLT to help understand the impact of IBD on graft survival.”
BackgroundSingh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318286fa61 · Cited by 94 · cited 1×
“49).(124) Therefore, while there might be a protective effect, more studies are needed to draw more definitive conclusions.”
BackgroundFevery, J., Van Steenbergen, W., Van Pelt, J., Laleman, W., Hoffman, I., Geboes, K., Vermeire, S., & Nevens, F. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13516 · Cited by 61
Cited by
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
The IBD and PSC phenotypes of PSC-IBD
Ricciuto, A., Kamath, B. M., & Griffiths, A. M. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0620-2 · Cited by 94
Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis
Hedin, C. R. H., Sado, G., Ndegwa, N., Lytvyak, E., Mason, A., Montano-Loza, A., Gerussi, A., Saffioti, F., Thorburn, D., Nilsson, E., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.014 · Cited by 52
Cauldwell, M., Mackie, F., Steer, P., Henehghan, M., Baalman, J., Brennand, J., Johnston, T., Dockree, S., Hedley, C., Jarvis, S., et al. (2020) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16119 · Cited by 46
Metadata
- Authors
- Palmela, C., Peerani, F., Castaneda, D., Torres, J., & Itzkowitz, S. H.
- Venue
- Gut and Liver
- Published
- 2018-01-15
- Volume
- 12
- Issue
- 1
- Pages
- 17-29
- ISSN
- 1976-2283 (ISSN-L)
- 2005-1212
- OpenAlex
- W2604695899
- Cited by
- 177
- References
- 18
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.